期刊文献+

恶性肿瘤患者乙型肝炎病毒感染状况的临床分析 被引量:4

下载PDF
导出
摘要 目的探讨恶性肿瘤患者乙型肝炎病毒(HBV)感染状况的临床特点。方法所有病例及对照组均用酶联免疫吸附试验(ELISA)法检测血清HBV 5项标志物(简称"两对半"),并作统计学分析。结果 810例各种恶性肿瘤患者HBV阳性共368例,阳性率为45.4%,其中肝癌患者的阳性率最高,达85.1%;其次为胃癌、食管癌、直肠癌,其阳性率分别为48.9%、45.5%、45.2%;肺癌、鼻咽癌、甲状腺癌、宫颈癌、白血病、恶性淋巴瘤的阳性率分别为32.4%、25.0%、28.8%、23.8%、35.8%、32.0%。与健康对照组比较,差异有统计学意义(P〈0.01~0.001),且消化道恶性肿瘤患者HBV感染的阳性率明显高于非消化道恶性肿瘤患者(P〈0.05~0.01)。结论该研究结果提示,恶性肿瘤患者与HBV关系密切,其真正原因有待进一步研究和探讨。
作者 谢力
出处 《检验医学与临床》 CAS 2011年第3期314-315,共2页 Laboratory Medicine and Clinic
  • 相关文献

参考文献7

二级参考文献37

  • 1褚士敏,韩存芝,马克荣,田翠英.恶性肿瘤患者乙肝病毒感染状况分析[J].肿瘤,1993,13(4):179-181. 被引量:6
  • 2郑怀竞.乙型肝炎病毒与血清标志物[J].肝脏病杂志,1993,1(3):181-182. 被引量:7
  • 3戴世凡,俞顺章,刘佩莉.原发性肝癌病例对照研究的多因素分析[J].肿瘤,1989,9(4):165-167. 被引量:3
  • 4乐晓华,陈心春,林巧,李美忠,王敏,刘赛云,余志勇,周伯平.慢性乙型肝炎患者肝组织中HBV抗原表达特征及其临床意义[J].中华实验和临床病毒学杂志,2007,21(1):41-43. 被引量:17
  • 5Sheen IS, Tsou YK, Lin SM, et al. Nuclear HBcAg and histology activity index as independent predictors of the expression of singly spliced HBV-RNA [J]. JViralHepat, 2007, 14(1): 70-74.
  • 6Frodsham AJ. Host genetics and the outcome of hepatitis B viral infection [J]. TransplImmunol, 2005, 14(3-4): 183-186.
  • 7Gerber MA, Hadziyannis S, Vissoulls C, et al. Electron microscopy and immunoelectronmicroscopy of cytoplasmic hepatitis B antigen in hepatocytes [ J]. Am J Pathol, 1974, 75 (3) : 489-502.
  • 8Aoki N, Gerber MA, Thung SN, et al. Uhrastructural studies of fibroblasts transfeeted with hepatitis B virus DNA [ J]. Hepatology, 1984, 4 ( 1 ) : 84-89.
  • 9Wang HC, Wu HC, Cben CF, et al. Different types of ground glass hepatoeytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress[J]. Am J Pathol, 2003, 163 (6) : 2441-2449.
  • 10Fan YF, Lu CC, Chang YC, et al. Identification of a pre-S2 mutant in hepatocytes expressing a novel marginal pattern of surface antigen in advanced diseases of chronic hepatitis B virus infection [ J]. J Gastroenterol Hepatol, 2000, 15(5) : 519-528.

共引文献34

同被引文献58

  • 1丁维军,王建华,杨海华,胡炜,邵明海.放疗加紫杉醇治疗晚期鼻咽癌患者医院感染的临床分析[J].中华医院感染学杂志,2006,16(4):398-400. 被引量:7
  • 2Hadgiyannis S, Tessopoulos N, Chang TJ, et al. Long- term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of fherapy[J]. Hepatology, 2005,42 : 754A-761A.
  • 3Lok AA, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B [J]. Gastroenterology, 2003,125(6) : 1714-1722.
  • 4Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence ofhepatitis B virus marker positivity and evolution of hepatitis B virusprofile, during chemotherapy, in patients with solid tumours. Br JCancer, 1999, 81(1) : 69-74.
  • 5Yeo W, Chan PK, Hui P,et al. Hepatitis B virus reactivation inbreast cancer patients receiving cytotoxic chemotherapy : a prospec-tive study. J Med Virol, 2003,70(4) : 553-561.
  • 6Targhetta C,Cabras MG,Mamusa AM,et al. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lym-phoma patients receiving chemo- or chemo-immune therapy.Haematologica, 2008,93(6) : 951-952.
  • 7Wands JR, Chura CM, Roll FJ, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumorchemotherapy for myeloproliferative and lymphoproliferative disor-ders. Gastroenterology, 1975 , 68(1): 105-112.
  • 8Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virusreactivation in cancer patients undergoing cytotoxic chemotherapy :a prospective study of 626 patients with identification of risk fac-tors. J Med Virol, 2000,62(3) : 299-307.
  • 9Yazdany J, Calabrese L. Preventing hepatitis B reactivation in im-munosuppressed patients : is it time to revisit the guidelines. Ar-thritis Care Res (Hoboken),2010, 62(5) : 585-589.
  • 10Alvarez-Sudrez B, de-la-Revilla-Negro J,Ruiz-Antordn B, et al.Hepatitis B reactivation and current clinical impact. Rev Esp En-ferm Dig, 2010,102(9) : 542-552.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部